Newsroom 2005
- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has completed its formerly announced public offering
of 4 million common shares. The common shares were sold in the United States and Canada at US$15.30 per share and all
common shares were offered by the company. The offering resulted in total gross proceeds to the company of approximately
US$61.2 million.
UBS Investment Bank acted as the sole book running manager in this offering, and CIBC World Markets Corp., Piper
Jaffray & Co., Desjardins Securities Inc., Wells Fargo Securities LLC, BMO Nesbitt Burns Inc. and Fortis
Securities LLC acted as co-managers.
Neurochem Inc. and its subsidiaries (Neurochem) intend to use the net proceeds from the offering to fund
Neurochem's clinical trials of its investigational product candidates, primarily Alzhemed™, as well as to further
complete pre-clinical and research and development programs and the balance for the marketing of Fibrillex™, working
capital and general corporate purposes.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be
any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such State.
About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying, oral products addresses critical, unmet medical needs.
1,3- propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug and a Fast Track Product candidate
and is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was recently concluded and the study data are expected to be
released in the second quarter of 2005. 3-amino-1-propanesulfonic acid (3APS; Alzhemed™), for the treatment of
Alzheimer's Disease, is in a Phase III clinical trial and 3APS; Cerebril™, for the prevention of Hemorrhagic Stroke
caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem Inc.'s control. The risks include but are not limited to: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem Inc. does business, stock market volatility, fluctuations in costs, and changes
to the competitive environment due to consolidation, as well as other risks disclosed in public filings of Neurochem
Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance ,if any, on the forward-looking statements
included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation
and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise.
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
